Browse BATF3

Summary
SymbolBATF3
Namebasic leucine zipper transcription factor, ATF-like 3
Aliases JUNDM1; SNFT; Jun dimerization protein 1; 21 kDa small nuclear factor isolated from T-cells; 21-kD small nuc ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00170 bZIP transcription factor
Function

AP-1 family transcription factor that controls the differentiation of CD8(+) thymic conventional dendritic cells in the immune system. Required for development of CD8-alpha(+) classical dendritic cells (cDCs) and related CD103(+) dendritic cells that cross-present antigens to CD8 T-cells and produce interleukin-12 (IL12) in response to pathogens (By similarity). Acts via the formation of a heterodimer with JUN family proteins that recognizes and binds DNA sequence 5'-TGA[CG]TCA-3' and regulates expression of target genes.

> Gene Ontology
 
Biological Process GO:0001773 myeloid dendritic cell activation
GO:0002274 myeloid leukocyte activation
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0009615 response to virus
GO:0030099 myeloid cell differentiation
GO:0043011 myeloid dendritic cell differentiation
GO:0097028 dendritic cell differentiation
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001078 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003714 transcription corepressor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolBATF3
Namebasic leucine zipper transcription factor, ATF-like 3
Aliases JUNDM1; SNFT; Jun dimerization protein 1; 21 kDa small nuclear factor isolated from T-cells; 21-kD small nuc ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BATF3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between BATF3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25446897MelanomaPromote immunityWithin these, CD103(+) DCs are extremely sparse and yet remarkably capable CTL stimulators. These are uniquely dependent on IRF8, Zbtb46, and Batf3 transcription factors and are generated by GM-CSF and FLT3L cytokines. Regressing tumors have higher proportions of these cells, T-cell-dependent immune clearance relies on them, and abundance of their transcripts in human tumors correlates with clinical outcome.
29316433Breast carcinomaIncrease the efficacy of immunotherapyGene expression analysis identified upregulation of Cxcl9 within intratumoral DCs during combination therapy, and therapeutic efficacy was ablated by CXCR3 blockade, Batf3 deficiency, or Irf8 deficiency.
19008445FibrosarcomaPromote immunityBatf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Importantly, rejection of highly immunogenic syngeneic tumors was impaired in Batf3-/- mice.
Summary
SymbolBATF3
Namebasic leucine zipper transcription factor, ATF-like 3
Aliases JUNDM1; SNFT; Jun dimerization protein 1; 21 kDa small nuclear factor isolated from T-cells; 21-kD small nuc ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BATF3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBATF3
Namebasic leucine zipper transcription factor, ATF-like 3
Aliases JUNDM1; SNFT; Jun dimerization protein 1; 21 kDa small nuclear factor isolated from T-cells; 21-kD small nuc ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BATF3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.710.0653
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.290.24
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2870.741
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.980.189
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.780.498
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.2430.377
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4570.224
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4030.508
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.530.41
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0410.289
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4660.761
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1730.262
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BATF3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBATF3
Namebasic leucine zipper transcription factor, ATF-like 3
Aliases JUNDM1; SNFT; Jun dimerization protein 1; 21 kDa small nuclear factor isolated from T-cells; 21-kD small nuc ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BATF3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBATF3
Namebasic leucine zipper transcription factor, ATF-like 3
Aliases JUNDM1; SNFT; Jun dimerization protein 1; 21 kDa small nuclear factor isolated from T-cells; 21-kD small nuc ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BATF3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BATF3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBATF3
Namebasic leucine zipper transcription factor, ATF-like 3
Aliases JUNDM1; SNFT; Jun dimerization protein 1; 21 kDa small nuclear factor isolated from T-cells; 21-kD small nuc ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BATF3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBATF3
Namebasic leucine zipper transcription factor, ATF-like 3
Aliases JUNDM1; SNFT; Jun dimerization protein 1; 21 kDa small nuclear factor isolated from T-cells; 21-kD small nuc ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BATF3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBATF3
Namebasic leucine zipper transcription factor, ATF-like 3
Aliases JUNDM1; SNFT; Jun dimerization protein 1; 21 kDa small nuclear factor isolated from T-cells; 21-kD small nuc ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BATF3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBATF3
Namebasic leucine zipper transcription factor, ATF-like 3
Aliases JUNDM1; SNFT; Jun dimerization protein 1; 21 kDa small nuclear factor isolated from T-cells; 21-kD small nuc ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BATF3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.